Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 7/20 | 0.33 |
| ▸ | CTSK | P43235 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14994052 | 0.74 | CYP2D6 (0.34) | MCL1CTSSCTSKCYP2D6CYP2C19 | |
| SCHEMBL6729276 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL1979548 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL4936016 | 0.71 | KDM4E (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL6898351 | 0.71 | KDM4E (0.48) | MCL1CYP2D6CYP2C19 | |
| SCHEMBL18125947 | 0.71 | KDM4E (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL6730282 | 0.71 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL26688828 | 0.71 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL27287336 | 0.70 | — | — | |
| SCHEMBL2340883 | 0.70 | MCL1 (0.33) | MCL1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | MCL1 327/4885SMN1; SMN2 445/4885HSD17B10 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.